Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth Premarin Biannual Price Increases To Boost "Cheap" 60[cents] Daily Cost

Executive Summary

Wyeth-Ayerst will adopt a biannual price increase strategy for the hormone replacement therapy Premarin, the company told analysts during its second quarter earnings call July 24.
Advertisement

Related Content

Premarin Family Sales Stabilize, Wyeth Says; Price Increases Help
Premarin Family Sales Stabilize, Wyeth Says; Price Increases Help
Wyeth Allocates Prempro/Premarin Inventories; Stocking Too High, Firm Says
Wyeth Premarin Plan For 2002: Stabilize Rxs Ahead Of Low-Dose Launch
Wyeth Premarin Plan For 2002: Stabilize Rxs Ahead Of Low-Dose Launch
Wyeth Premarin Shortage Is Opportunity To Shift Patients To Cenestin – Barr
Third Quarter Conference Calls, In Brief
Lilly Tries To Boost Evista Profile Via Comparative Trial With Fosamax
Wyeth Low-Dose PremPro Osteoporosis sNDA Filing Planned For June
Wyeth Low-Dose PremPro Osteoporosis sNDA Filing Planned For June
Advertisement
UsernamePublicRestriction

Register

PS038274

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel